GlassScriptPhysician profile
Terri Duncan
NPI 1750501326
$11,722.02
in general payments reported to CMS, 2019-2025
43 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,968 · 2022: $1,957 · 2023: $2,060 · 2024: $2,462 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,789 · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,788.64 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,240.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,627.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $941.04 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $818.11 | 2021-2025 | |
| Lilly USA, LLC | $775.57 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $640.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $578.35 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $441.78 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $321.91 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $262.58 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $256.63 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.81 | 2021-2024 | Synjardy, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $222.20 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $206.87 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $181.30 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.